gynecomastia in 44 yo patient with HFrEF and persistent elevated liver funtion

Management of Gynecomastia in a 44-year-old Patient with Heart Failure with Reduced Ejection Fraction and Persistent Elevated Liver Function Tests

Gynecomastia in adult men, such as a 44-year-old, can be multifactorial, stemming from hormone changes, medications, and systemic conditions including liver disease NHS Gynaecomastia. In a patient with heart failure with reduced ejection fraction (HFrEF), medications contributing to gynecomastia, such as aldosterone antagonists, should be considered as potential causes, especially given the persistence of elevated liver function tests which may indicate underlying hepatic dysfunction NHS Gynaecomastia,NICE NG106,Netala et al. 2024. Aldosterone antagonists, commonly used in HFrEF management, carry the risk of causing gynecomastia in men NICE NG106,Netala et al. 2024. Persistent elevated liver function tests suggest liver impairment, which can itself contribute to hormonal imbalances promoting gynecomastia NHS Gynaecomastia.

Clinical Approach:

• Conduct a thorough clinical assessment to confirm gynecomastia and exclude male breast cancer or other pathologies by evaluating for pain, lumps, nipple changes, or discharge NHS Gynaecomastia.
• Review current medications, focusing on heart failure drugs like spironolactone, which is known to cause gynecomastia, and consider substituting with alternatives if appropriate and feasible NHS Gynaecomastia,NICE NG106.
• Optimize heart failure therapy per guidelines employing a combination of ACE inhibitors or ARBs, beta-blockers, mineralocorticoid receptor antagonists (MRA), and SGLT2 inhibitors with close monitoring, including liver and renal function tests NICE CKS,NICE NG106,Louca et al. 2025. This may necessitate specialist input to carefully titrate medications while balancing side effects.
• If aldosterone antagonist therapy is essential but gynecomastia persists, consider switching to eplerenone, which has a lower incidence of this side effect, or adjust doses accordingly NICE NG106,Netala et al. 2024.
• Address elevated liver function tests by evaluating for causes such as hepatic congestion due to heart failure or primary liver disease, and manage accordingly to help correct hormonal imbalances contributing to gynecomastia NHS Gynaecomastia,Netala et al. 2024.
• Non-pharmacological options such as weight loss may reduce gynecomastia if the patient is overweight NHS Gynaecomastia.
• Pharmacological treatments targeting gynecomastia, like tamoxifen, are generally reserved for persistent, painful, or cosmetically problematic cases and usually require specialist referral NHS Gynaecomastia.
• Surgical intervention may be considered if medical and conservative measures fail, but availability on the NHS may be limited NHS Gynaecomastia.

Monitoring and Follow-Up:

• Regular monitoring of heart failure status and liver function tests is crucial, especially during medication titration and adjustment phases NICE CKS,NICE NG106,Louca et al. 2025.
• Utilize home-based monitoring where appropriate to optimize heart failure therapy quickly and safely, as demonstrated by recent studies on standardized titration supported by telemonitoring Louca et al. 2025, ensuring adverse effects like gynecomastia are monitored.

In summary, managing gynecomastia in this patient involves ruling out serious causes, reviewing and potentially modifying heart failure medications (especially mineralocorticoid receptor antagonists), addressing liver dysfunction, and considering specialist referral if gynecomastia persists or impacts quality of life significantly NHS Gynaecomastia,NICE NG106,Louca et al. 2025.